ulifloxacin has been researched along with levofloxacin in 7 studies
Studies (ulifloxacin) | Trials (ulifloxacin) | Recent Studies (post-2010) (ulifloxacin) | Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) |
---|---|---|---|---|---|
50 | 3 | 15 | 4,346 | 581 | 2,209 |
Protein | Taxonomy | ulifloxacin (IC50) | levofloxacin (IC50) |
---|---|---|---|
Replicase polyprotein 1ab | Betacoronavirus England 1 | 7.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (85.71) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Eda, T; Hosaka, M; Hoshino, K; Inoue, M; Kaieda, S; Kitasato, H; Kuga, A; Okamoto, R; Sato, Y; Seto, I | 1 |
Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
Hikida, M; Kariyama, R; Kato, Y; Kumon, H; Mikuniya, T; Monden, K | 1 |
Cochetti, I; Minardi, D; Mingoia, M; Montanari, MP; Muzzonigro, G; Tili, E; Varaldo, PE | 1 |
Di Maggio, T; Mantengoli, E; Montagnani, F; Pallecchi, L; Pollini, S; Riccobono, E; Rossolini, GM | 1 |
7 other study(ies) available for ulifloxacin and levofloxacin
Article | Year |
---|---|
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Quinolones; Respiratory Tract Infections; Sepsis | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Fluoroquinolones; Fosfomycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones | 2005 |
Effects of fluoroquinolones on bacterial adhesion and on preformed biofilm of strains isolated from urinary double J stents.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Biofilms; Dose-Response Relationship, Drug; Enterococcus; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones; Staphylococcus; Stenotrophomonas maltophilia; Stents; Ureteral Calculi | 2008 |
Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pneumococcal Infections; Streptococcus pneumoniae | 2011 |